Back to News
Market Impact: 0.18
Jaguar Health Receives Fee Waivers from FDA
Source: Newswire
Healthcare & BiotechCorporate Guidance & OutlookProduct Launches
The company reaffirmed its focus on global development of crofelemer powder for oral solution in rare intestinal-failure indications, including microvillus inclusion disease (MVID) and short bowel syndrome (SBS). It is targeting a mid-2027 New Drug Application filing for MVID, providing a long-dated regulatory-development milestone but no new clinical or financial data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- Trump Says US Team Met With Iranians at UNGA
- Paramount will need to release way more movies to make this merger work
- Meta is breaking out after introducing Muse AI agent. Where the stock is going, according to the charts
- Heidi CEO on AI in Healthcare, $900M valuation
- Meta’s Muse AI is exploding in popularity—and already drawing heated backlash from another tech giant
- Royal Caribbean nears $3 billion deal to take 50% equity stake in Sandals
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Capital Intensity as Gravity: The AI Trade Enters Its Industrial Era (Looking at Q3 2025 Earnings in Tech)
- AI Portfolio Monitoring: Build an Alert Policy Analysts Can Audit